GSA Capital Partners LLP grew its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 84.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 571,613 shares of the biotechnology company’s stock after purchasing an additional 262,084 shares during the period. GSA Capital Partners LLP’s holdings in Ironwood Pharmaceuticals were worth $1,926,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Calamos Advisors LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at $49,000. Integrated Wealth Concepts LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares in the last quarter. Vise Technologies Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $39,000. BNP Paribas Financial Markets lifted its holdings in shares of Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 15,594 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Ironwood Pharmaceuticals by 474.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,090 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 29,810 shares in the last quarter.
Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total transaction of $20,528,940.00. Following the transaction, the director directly owned 9,188,635 shares in the company, valued at $28,025,336.75. This trade represents a 42.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 9.30% of the stock is currently owned by company insiders.
Ironwood Pharmaceuticals Trading Up 4.9%
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The firm had revenue of $106.51 million for the quarter, compared to analysts’ expectations of $92.11 million. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.88 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on IRWD. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Citizens Jmp increased their price objective on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $3.70 price objective on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.23.
Read Our Latest Research Report on IRWD
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
